After decades of limited progress, the development of novel anti-TB medicines was revitalised at the start of the 21st century through new initiatives and investments. This has resulted in innovations in treatment regimens thanks to new compounds becoming available and the re-purposing of existing drugs. However, progress has been relatively slow for a disease that, until the emergence of the COVID-19 pandemic, has remained the top infec- tious killer worldwide. Accelerated action is there- fore necessary to reach the ambitious target of ‘‘ending TB’’ set by the WHO within its new Global Strategy (2016–2030). Read Here.
top of page
Recent Posts
See AllA recent study on the incidence of MDR-TB in children and teens revealed that the prevalence has resurged. there was a 10 year drop from...
The Stop TB Partnership announced a major price reduction on bedaquiline. The cost per treatment course was slashed by over 50%,...
The shutdown and dismantling of USAID has had large ramifications for TB services. As one of the largest funding sources for TB, the...
bottom of page
Comments